PM01183 . Edison Investment Research ya Emitió un Informe sobre las Espectativas para Zeltia con este Farmaco en febrero de este año , unas Espectativas que en el Congreso ESMO-13 no solo se Ratificaran sino que incluso ... Mejoraran . Fase III Ovario ya Preparandose , Fase II Pulmón en Breve Inició , Fase II Mama , Pancreas , Leucemia , Fase I Colón ...

La Comunidad Cientifica es Rotunda :

" Encontar una Nueva Terapia que Supere la Resistencia a los Platinos es una Prioridad " .

Resultados Fase II con PM01183 frente a Topotecan para el Tratamiento del Cáncer de Ovario Resistente/Refractario a Platino el 30% de las Enfermas Tratadas con PM01183 mostraron Respuesta Objetiva al Tratamiento, mientras que de las Pacientes Tratadas con Topotecan No se Registró Ninguna Respuesta Objetiva.
Spain's Zeltia is Turning a Corner, Say Edison Analysts .

ThisShareThisSpanish drugmaker Grupo Zeltia (ZEL: MC) is approaching a material catalyst this year in the form of the read-out from its Phase II study of lurbinectedin (PM01183) in platinum resistant ovarian cancer, say analysts at Edison Investment Research.

If positive, this could form the basis of a licensing deal that could transform Zeltia’s fortunes, they believe.

...

These data are due in the second half of 2013 and could be the catalyst for a partnership that should support mid- to late-stage development in other solid tumor types; activity has already been demonstrated in breast, lung and pancreatic cancers. Two Phase II studies in lung cancer (non-small cell and small cell lung cancer) are due to start in mid-2013, and a Phase II trial in breast cancer is due to read-out in 2015.

Valuation hinges on positive data

Thus a material pipeline catalyst and the chance of a licensing deal could give new impetus to a recovery in the shares this year, the analysts conclude.

...